Refine by
Positive Patients Articles & Analysis: Older
81 news found
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...
The research study, conducted at Mount Sinai Icahn School of Medicine, included 53 adult patients undergoing primary ablative surgery of the oral cavity or oropharynx for squamous cell carcinoma (SCC). ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and ...
A post-hoc analysis of the PFS results in the EMERALD trial based on the duration of prior CDK4/6i usage shows clinically meaningful results which favor monotherapy elacestrant, both in the total patient population as well as in patients with ESR1-mut. Increased duration of prior CDK4/6i in metastatic patients was positively ...
(“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ...
The study demonstrated an incremental cost-effectiveness ratio (ICER) of $17,000 per quality-adjusted life year gained, which is the academic standard for measuring how well medical treatments lengthen and/or improve patients' lives. The ICER is substantially lower than accepted willingness-to-pay thresholds in the U.S. and other healthcare systems. ...
Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness remotely. This is paving the way for improving patient care as ePROMs can be used to monitor patients with reported health conditions coming directly from the patient, ...
As communicated on 23 September 2021, treatment with Diamyd® in individuals recently diagnosed with type 1 diabetes carrying HLA DR3-DQ2 led to statistically significant positive treatment effects on longer time in the glycemic target range (TIR), reduced time in hyperglycemia, and reduced increase in glucose variability over the 15-month study period compared to ...
Updated 12-month results presented today at EASD The updated results provide additional support for a positive immunological and metabolic response in LADA patients with HLA DR3-DQ2. ...
The AeriSeal System is used to close collateral air channels in a target lung lobe of a patient with severe COPD/emphysema, making the patient eligible to then undergo Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Valves. ...
“But by using a patient’s NGS data and Cellworks SingulaTM to biosimulate their individual therapy responses, we can potentially improve the ability to select the most effective therapy for each GBM patient and positively effect clinical outcomes for brain cancer ...
” The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. ...
FDA for the reduction of SOM induced by radiotherapy, and we look forward to submitting a New Drug Application to the FDA by year end in order to bring this potential treatment to patients as quickly as possible.” Results from the 455-patient Phase 3 trial demonstrated a meaningful reduction in patients’ SOM burden across multiple ...
Excite Medical hopes to create a bigger platform for themselves as a company in its field in effort to provide a healthier and non-surgical alternative approach for patients suffering from chronic back and neck pain and symptoms associated with herniated discs, bulging or protruding inter-vertebral discs, degenerative disc disease, posterior facet syndrome, and sciatica. ...
Lost in the surgical backlog, already delayed diagnoses may be further delayed, potentially lowering patient outcomes. That’s why early detection is crucial; for patients with local to regional prostate cancer (PCa), the 5 year survival rate is nearly 100%, but drops to 30% once the cancer begins to spread to other organs.1 The current standard diagnostic ...
A Phase I clinical study will be conducted in Chinese patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced/metastatic breast cancer, including patients who are resistant to approved CDK4/6 inhibitors, to evaluate the safety, tolerability and pharmacokinetic profile of RGT-419B capsule. ...
The practitioner plans the implants intraoperatively in relation to the image of the patient in the intervention position, thanks to automatic pre-positioning, and adjusts the position and orientation of the implants on the intuitive interface. ...
We are pleased with the successful commercial launch and are impressed by the positive patient outcomes and growth potential of this innovative technology. ...
We are now developing a device that captures patient temperature and patient detail and automatically uploads that information to a hospital database, improving efficiency in nurse’s time (economic challenge), minimizing risk of cross-infection (societal challenge evidenced particularly during Covid), with a plastic-free, environmentally-friendly solution ...
The Notal Home OCT pipeline technology is designed to provide patient-initiated retinal OCT scans to support the management of patients with wet age-related macular degeneration (AMD), complementing existing standard of care treatments as well as emerging longer acting drugs and drug delivery systems. ...